Stock OPK OPKO HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.26 USD +3.28% Intraday chart for OPKO Health, Inc. +2.44% -16.56%
Mar. 28 Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets MT
Mar. 20 Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 978.4 2,647 3,276 965.9 1,167 878.2 - -
Enterprise Value (EV) 1 978.4 2,647 3,276 965.9 1,167 878.2 878.2 878.2
P/E ratio -2.77 x 79 x -96.2 x -2.72 x -6.04 x -3.45 x -4.91 x -28 x
Yield - - - - - - - -
Capitalization / Revenue 1.08 x 1.84 x 1.85 x 0.96 x 1.35 x 1.18 x 1.1 x 1.01 x
EV / Revenue 1.08 x 1.84 x 1.85 x 0.96 x 1.35 x 1.18 x 1.1 x 1.01 x
EV / EBITDA -7.42 x 24 x 91.5 x -6.1 x -16.2 x -12.5 x 23.7 x 10.2 x
EV / FCF -5.28 x 457 x 530 x - -26.2 x -8.16 x -21.8 x -517 x
FCF Yield -18.9% 0.22% 0.19% - -3.81% -12.3% -4.58% -0.19%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 665,601 670,000 681,099 772,686 773,057 696,992 - -
Reference price 2 1.470 3.950 4.810 1.250 1.510 1.260 1.260 1.260
Announcement Date 2/26/20 2/18/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 901.9 1,435 1,775 1,004 863.5 745.3 795.6 872.9
EBITDA 1 -131.8 110.1 35.8 -158.4 -72 -70.4 37.1 85.8
EBIT 1 -274.1 57.7 18.7 -226.3 -157 -240.6 -202.6 -25.7
Operating Margin -30.39% 4.02% 1.05% -22.54% -18.18% -32.29% -25.46% -2.94%
Earnings before Tax (EBT) 1 -304.9 48.7 -14 -391.5 -184.4 -257.2 -183.4 -34.9
Net income 1 -314.9 30.6 -30.1 -328.4 -188.8 -258.7 -185.4 -32.05
Net margin -34.92% 2.13% -1.7% -32.7% -21.86% -34.71% -23.3% -3.67%
EPS 2 -0.5300 0.0500 -0.0500 -0.4600 -0.2500 -0.3650 -0.2567 -0.0450
Free Cash Flow 1 -185.3 5.794 6.181 - -44.47 -107.6 -40.2 -1.7
FCF margin -20.54% 0.4% 0.35% - -5.15% -14.44% -5.05% -0.19%
FCF Conversion (EBITDA) - 5.26% 17.27% - - - - -
FCF Conversion (Net income) - 18.93% - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/26/20 2/18/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 385.8 401.3 329.2 309.9 179.7 185.4 237.6 265.4 178.6 181.9 183 187 186.3 188.9 193
EBITDA 1 18.43 -50.7 -50.5 -3.1 -67.2 -37.5 -9 28.5 -44 -47.6 -26.8 -19.3 -15.3 -9 -
EBIT 1 6.318 -63.1 -72.4 -10.7 -87.8 -55.3 -30.6 7 -64.4 -69.1 -65.28 -62.09 -58.72 -54.51 -45.46
Operating Margin 1.64% -15.72% -21.99% -3.45% -48.86% -29.83% -12.88% 2.64% -36.06% -37.99% -35.67% -33.2% -31.52% -28.86% -23.55%
Earnings before Tax (EBT) 1 31.47 -65.8 -76.6 -86.3 -126.4 -102.2 -17 -16.5 -78.4 -72.5 -66.8 -66.3 -64.08 -58.91 -47.49
Net income 1 28.74 -73.8 -55.4 -101.7 -86.1 -85.2 -18.3 -19.6 -84.5 -66.5 -67.2 -66.52 -64.59 -59.26 -47.29
Net margin 7.45% -18.39% -16.83% -32.82% -47.91% -45.95% -7.7% -7.39% -47.31% -36.56% -36.72% -35.56% -34.66% -31.37% -24.5%
EPS 2 0.0400 -0.1100 -0.0800 -0.1400 -0.1100 -0.1100 -0.0200 -0.0300 -0.1100 -0.0900 -0.0950 -0.0950 -0.0917 -0.0833 -0.0700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/24/22 5/9/22 8/4/22 11/8/22 2/23/23 5/3/23 8/3/23 11/6/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -185 5.79 6.18 - -44.5 -108 -40.2 -1.7
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 12.7 33.7 32.2 - 16.3 20 21 35
Capex / Sales 1.41% 2.35% 1.81% - 1.88% 2.68% 2.64% 4.01%
Announcement Date 2/26/20 2/18/21 2/24/22 2/23/23 2/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for OPKO Health, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.26 USD
Average target price
4.25 USD
Spread / Average Target
+237.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
OPKO HEALTH, INC. Stock OPKO Health, Inc.
-16.56% 878M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.89% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.46B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.35% 2.38B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-12.61% 1.81B
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. OPK Stock
  4. Financials OPKO Health, Inc.